Abstract
Summary OncoCTMiner is an innovative platform that streamlines precision oncology trial matching by integrating genetic profile analysis and clinical data. It utilizes manual tagging and automated entity recognition to identify six major biomedical concepts within clinical trial records. The platform currently contains a database of over 457,000 clinical trials, enabling quick and advanced search functionalities. Additionally, OncoCTMiner features an automated matching system based on genetic profiles and clinical data, providing real-time matching reports for suitable clinical trials. This platform aims to enhance patient enrollment in precision oncology trials, facilitating the development of personalized cancer therapies.
Availability and Implementation OncoCTMiner is available at https://oncoctminer.chosenmedinfo.com.
Contact niubf{at}cnic.cn or qimingzhou{at}chosenmedtech.com
Supplementary information Supplementary data are available at medRxiv online.
A) OncoCTMiner’s role in precision oncology trial enrollment. B) OncoCTMiner takes clinical and genetic profiles as inputs and utilizes a trial matching and filtering system to generate a report of matched trials. C) Strategy for building the clinical trial eligibility criteria database. D) Automatic matching strategy for genomics-driven oncology trials.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Natural Science Foundation of China [grant number 92259101, 31771466], Strategic Priority Research Program of the Chinese Academy of Sciences, China [grant number XDB38040100], and the Cancer Genome Atlas of China (CGAC) project (YCZYPT [2018]06) from the National Human Genetic Resources Sharing Service Platform (2005DKA21300).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.